Heart failure medications with an Impella heart pump for cardiogenic shock
Part of Heart & circulation clinical trials.
This study tests whether a special heart pump (Impella 5.5) can help patients with severe heart failure (cardiogenic shock) safely start and increase their heart failure medications. The goal is to see if this approach can help the heart recover and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your heart's pumping ability (left ventricular ejection fraction) must be 40% or less.
- You must be in a type of severe heart failure called cardiogenic shock, meaning your heart isn't pumping enough blood to meet your body's needs.
- You are not already on optimal heart failure medications—you're on two or fewer of the four main drug classes, or you're on low doses of them.
- You are not on certain other heart assist devices (like ECMO) or a ventilator before starting the study.
- You do not have conditions that would prevent you from getting the heart pump (Impella 5.5) used in this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a temporary heart pump (Impella) can help people with severe heart failure and cardiogenic shock (when the heart can't pump enough blood). The goal is to see if this device can reduce fluid buildup and improve blood flow, but it's for people who are very ill and need extra support.
This study tests whether using a temporary heart pump called Impella 5.5 can help strengthen a very weak and enlarged heart (dilated cardiomyopathy) in people who are waiting for a heart transplant. If you qualify, the pump is placed to support your heart temporarily, and the research team will check how your heart responds.
This study reviews how well people tolerated the Impella heart pump during cardiogenic shock and what complications occurred. It looks at past cases from 2010 to 2022 to help doctors understand the safety of this device.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This study examines detailed data from patients who received an Impella 5.5 heart pump to treat cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood. Researchers use advanced computer analysis to understand what helps patients recover best.
This study looks at when to insert a small heart pump (Impella CP) in people who have had a heart attack and are in cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to find out if placing the pump before or after the artery-opening procedure improves outcomes.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.